Allergic rhinitis (AR) is estimated to affect 20–25% of the United States population and thus accounts for a significant portion of our annual total health care expenditure, especially when one includes all of the concomitant disorders associated with rhinitis such as asthma and sinusitis. Given the prevalence of chronic rhinitis, the significant comorbidities associated with this condition, its overall health burden, and dissatisfaction by allergy sufferers with treatment outcomes, it is essential that the allergist and otolaryngologist develop a consensus approach for the evaluation, diagnosis, and treatment of chronic rhinitis subtypes.
Methods
This study was designed to achieve this end point. Investigators have taken several clinical, physiological, and mechanistic approaches toward better characterizing rhinitis subtypes. An accurate diagnosis directed at differentiating AR, nonallergic rhinitis, and mixed rhinitis is essential to ensure that treatment(s) prescribed will lead to more favorable clinical outcomes.
Results
An accurate history taking into account age of symptom onset, family history, quantification of inciting allergic and/or nonallergic triggers, and seasonality followed by aeroallergen skin testing to assess atopic status has been shown to be the most useful approach for clearly differentiating rhinitis subtypes.
Conclusion
Other cellular, cytokine, genetic, and physiological markers have thus far been proven to be less useful. Ultimately, treatment response to medications will be most effective when they are individualized to the patient's diagnosis.
Get full access to this article
View all access options for this article.
References
1.
BellantiJA and WallerstedtDB. Allergic rhinitis update: Epidemiology and natural history. Allergy Asthma Proc21:367–370, 2000.
2.
KalinerMA. Classification of nonallergic rhinitis syndromes with a focus on vasomotor rhinitis, proposed to be known henceforth as nonallergic rhinopathy. World Allergy Organ J2:98–101, 2009.
3.
DereberyJMeltzerENathanRA, Rhinitis symptoms and comorbidities in the United States: Burden of rhinitis in America survey. Otolaryngol Head Neck Surg139:198–205, 2008.
4.
NathanRAMeltzerEODereberyJ, The prevalence of nasal symptoms attributed to allergies in the United States: Findings from the burden of rhinitis in an America survey. Allergy Asthma Proc29:600–608, 2008.
5.
MeltzerEOBlaissMSDereberyMJ, Burden of allergic rhinitis: Results from the pediatric allergies in America survey. J Allergy Clin Immunol124(suppl 3):S43–S70, 2009.
6.
MeltzerEONathanRADereberyMJ, Sleep, quality of life, and productivity impact of nasal symptoms in the United States: Findings from the burden of rhinitis in America survey. Allergy Asthma Proc30:244–254, 2009.
7.
GreisnerWAIIISettipaneRJ and SettipaneGA, Co-existence of asthma and allergic rhinitis: A 23-year follow-up study of college students. Allergy Asthma Proc19:185–188, 1998.
8.
SettipaneRA. Complications of allergic rhinitis. Allergy Asthma Proc20:209–213, 1999.
9.
MeltzerEO, Burden of allergic rhinitis: Allergies in America, Latin America, and Asia-Pacific Adult surveys. Allergy Asthma Proc33(suppl 1):S113–S141, 2012.
10.
AndersonGP. Endotyping asthma: New insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet372:1107–1119, 2008.
11.
HaldarPPavordIDShawDE, Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med178:218–224, 2008.
12.
Di LorenzoGPacorMLAmodioE, Differences and similarities between allergic and nonallergic rhinitis in a large sample of adult patients with rhinitis symptoms. Int Arch Allergy Immunol155:263–270, 2011.
13.
BernsteinJA. Characteristics of nonallergic vasomotor rhinitis. World Allergy Organ J2:102–105, 2009.
14.
RezvaniMBrandtDBernsteinJA, Investigation of olfactory threshold responses in chronic rhinitis subtypes. Ann Allergy Asthma Immunol99:571–572, 2007.
Brasch-AndersenCHaagerupABorglumAD, Highly significant linkage to chromosome 3q13.31 for rhinitis and related allergic diseases. J Med Genet43:e10, 2006.
17.
BensonMMobiniRBarrenäsF, A haplotype in the inducible T-cell tyrosine kinase is a risk factor for seasonal allergic rhinitis. Allergy64:1286–1291, 2009.
18.
HusseinYMAhmadASIbrahemMM, Interferon gamma gene polymorphism as a biochemical marker in Egyptian atopic patients. J Investig Allergol Clin Immunol19:292–298, 2009.
19.
SettipaneRA and LiebermanP.Update on nonallergic rhinitis. Ann Allergy Asthma Immunol86:494–507, 2001.
20.
BrandtD and BernsteinJA. Questionnaire evaluation and risk factor identification for nonallergic vasomotor rhinitis. Ann Allergy Asthma Immunol96:526–532, 2006.
21.
BrandtD and BernsteinJA. Questionnaire diagnosis of nonallergic rhinitis. Clin Allergy Immunol19:55–67, 2007.
22.
BernsteinJA. Allergic and mixed rhinitis: Epidemiology and natural history. Allergy Asthma Proc31:365–369, 2010.
23.
BernsteinJALevinLSAl-ShuikE and MartinVT. Clinical characteristics of chronic rhinitis patients with high vs low irritant trigger burdens. Ann Allergy Asthma Immunol109:173–178, 2012.
24.
RondónCCampoPGalindoL, Prevalence and clinical relevance of local allergic rhinitis. Allergy67:1282–1288, 2012.
25.
RondónCCampoPTogiasA, Local allergic rhinitis: Concept, pathophysiology, and management. J Allergy Clin Immunol129:1460–1467, 2012.
26.
GelardiMFiorellaMLRussoC, Role of nasal cytology. Int J Immunopathol Pharmacol23(suppl):45–49, 2010.
27.
GratziousCRovinaNMakrisM, Breath markers of oxidative stress and airway inflammation in seasonal allergic rhinitis. Int J Immunopathol Pharmacol21:949–957, 2008.
28.
KalpakliogluAF and KalkanIK. Comparison of orally exhaled nitric oxide in allergic versus nonallergic rhinitis. Am J Rhinol Allergy26:e50–e54, 2012.
29.
ScaddingG and ScaddingGK. Update on the use of nitric oxide as a noninvasive measure of airways inflammation. Rhinology47:115–120, 2009.
30.
TimperleyDSrubiskyAStowN, Minimal clinically important differences in nasal peak inspiratory flow. Rhinology49:37–40, 2011.
31.
UzzamanAMetcalfeDD and KomarowHD, Acoustic rhinometry in the practice of allergy. Ann Allergy Asthma Immunol97:745–751, 2006.
32.
BernsteinJASalapatekAMLeeJS, Provocation of nonallergic rhinitis subjects in response to simulated weather conditions using an environmental exposure chamber model. Allergy Asthma Proc33:333–340, 2012.
33.
JacobsRIHarperNHeW, Responses to ragweed pollen in a pollen challenge chamber versus seasonal exposure identify allergic rhinoconjunctivitis endotypes. J Allergy Clin Immunol130:122–127.e8, 2012.
34.
TantilipikornPThanaviratananichSChusakulS, Efficacy and safety of once daily fluticasone furoate nasal spray for treatment of irritant (non-allergic) rhinitis. Open Respir Med J4:92–99, 2010.
35.
WallaceDVDykewiczMSBernsteinDI, The diagnosis and management of rhinitis: An updated practice parameter. J Allergy Clin Immunol122(suppl):S1–S84, 2008.
36.
BanovCHLiebermanP and the Vasomotor Rhinitis study. Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis. Ann Allergy Asthma Immunol86:28–35, 2001.
37.
CarrWBernsteinJLiebermanP, A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol129:1282–1289.e10, 2012.
38.
SmithAMRezvaniM and BernsteinJA. Is response to allergen immunotherapy a good phenotypic marker for differentiating between allergic rhinitis and mixed rhinitis?Allergy Asthma Proc32:49–54, 2011.
39.
BeckerBBorumSNielsenK, A time-dose study of the effect of topical ipratropium bromide on methacholine-induced rhinorrhea in patients with perennial non-allergic rhinitis. Clin Otolaryngol Allied Sci22:132–134, 1997.
